<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="en">
<head>
	<meta charset="utf-8"/>
	<title>General Surgery - Clerkship Handbook</title>
	<meta name="author" content="Salpy Kelian"/>
	<meta name="date" content="July, 2017"/>
	<link type="text/css" rel="stylesheet" href="main.css"/>
</head>
<body>

<p><!--add ins--> <meta http-equiv="cleartype" content="on"> <meta name="MobileOptimized" content="320"> <meta name="HandheldFriendly" content="True"> <meta name="apple-mobile-web-app-capable" content="yes"> <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no"> <!--/end add ins--> <script src="jquery-3.2.1.slim.min.js" crossorigin="anonymous"></script> <script src="stacktable.js"></script> <script src="slideout.min.js"> <script src="source.js"></script><br />
<link href="hamburger.css" rel="stylesheet" type="text/css" />
<link rel="manifest" href="manifest.json">
<link href="main.css" rel="stylesheet" type="text/css" /></p>

<p><nav id="menu">
<input type="search" class="search" placeholder="Search" /></p>

<div class="TOC">

<ul>
<li><a href="#bloodbloodproducts">Blood &amp; Blood Products </a>
<ul>
<li><a href="#volume">Volume </a></li>
<li><a href="#products">Products </a>
<ul>
<li><a href="#adverseeffects">Adverse Effects </a>
<ul>
<li><a href="#symptomstobeawareofposttransfusion">Symptoms to Be Aware of Post Transfusion </a></li>
</ul>
</li>
</ul>
</li>
<li><a href="#coagulation">Coagulation </a>
<ul>
<li><a href="#controlofbloodclotting">Control of Blood Clotting </a>
<ul>
<li><a href="#heparin">Heparin </a></li>
<li><a href="#warfarin">Warfarin </a></li>
<li><a href="#neworalanticoagulants">New Oral Anticoagulants </a></li>
<li><a href="#fibrinolytics">Fibrinolytics </a></li>
<li><a href="#anti-platelet">Anti-platelet </a></li>
</ul>
</li>
</ul>
</li>
</ul>
</li>
<li><a href="#sutures">Sutures </a>
<ul>
<li><a href="#generalrules">General Rules </a></li>
</ul>
</li>
</ul>
</div>

<p></nav>
<header class="fixed-header"><button class="hamburger hamburger--squeeze js-slideout-toggle" type="button"><span class="hamburger-box"><span class="hamburger-inner"></span></span></button></header></p>

<main id="main">
<h1>General Surgery - Clerkship Handbook</h1>
<small>This is a work in progress for McMaster's General Surgery Clerkship - WRC Campus. Last updated Sept 1, 2017 - by Salpy Kelian</small><br/>

<h1 id="bloodbloodproducts">Blood &amp; Blood Products </h1>

<h2 id="volume">Volume </h2>

<ul>
<li>100 mL/kg if &le; 2 kg</li>
<li>80 mL/kg if &gt; 2kg</li>
</ul>

<h2 id="products">Products </h2>

<table>
<colgroup>
<col style="text-align:left;"/>
<col style="text-align:left;"/>
<col style="text-align:left;"/>
</colgroup>

<thead>
<tr>
	<th style="text-align:left;">Product	</th>
	<th style="text-align:left;"> Use	</th>
	<th style="text-align:left;"> Other Details	</th>
</tr>
</thead>

<tbody>
<tr>
	<td style="text-align:left;"><strong>PRBC</strong><br>packed red blood cells	</td>
	<td style="text-align:left;"> <li>replacement of blood loss, increases Hb: transfuse when &lt; 70 g/L, do not correct to &gt; 90 g/L <li>1 unit &uparrow; Hct by 3&#8211;4% (&uparrow; Hb 10 g/L)<li>must be ABO and Rh compatible	</td>
	<td style="text-align:left;"> <li>1 unit ~ 300mL (from one donor)<li>42 day frozen shelf life <li>&downarrow; viability with age<li>increased K^+ with age<li>no clotting factors<li>lasts in recipient circulation for 5&#8211;6 wks<li>massive transfusion if &gt;10 units/24 hours or 3 units/hour</td>
</tr>
<tr>
	<td style="text-align:left;"><strong>FFP</strong><br/>fresh frozen plasma</td>
	<td style="text-align:left;"> <li>replacement of coagulation factors (physiological concentrations) in cases of: abnormal &uparrow; INR or aPTT, dilution (e.g. massive transfusion protocol), anticoagulant medications requiring rapid reversal (e.g. warfarin)<li>1 unit &uparrow; by coagulation factors by 1%<li>must be ABO compatible	</td>
	<td style="text-align:left;"><li>1 unit ~ 200&#8211;300 mL (pooled from multiple donors) <li>has no RBCs/WBCs/platelets <li>frozen shelf life of 12 months <li> must be used within 24 hours once thawed</td>
</tr>
<tr>
	<td style="text-align:left;"><strong>Platelets</strong></td>
	<td style="text-align:left;"> <li>used when platelets are &lt; 50&#8211;100 x 10<sup>9</sup>/L <li>1 unit has ~ 3&#8211;4x10<sup>11</sup> platelets	</td>
	<td style="text-align:left;"> <li>1 unit ~ 300 mL (pooled from ~ 6 donors) <li>may have some RBC/WBC <li>shelf life of 5 days (stored at room temp) <li>post transfusion count peaks at 10&#8211;60 min and &downarrow; over 72 hrs</td>
</tr>
<tr>
	<td style="text-align:left;"><strong>Cryoprecipitate</strong> </td>
	<td style="text-align:left;"> <li>used when bleeding is due to &downarrow; fibrinogen: massive transfusion protocols, postpartum hemorrhage, DIC <li> 1 unit &uparrow; fibrinogen by 0.7&#8211;1 g/L</td>
	<td style="text-align:left;"> <li>1 unit ~ 50&#8211;200 mL (pool of 5&#8211;10 donors) <li>a fraction of plasma rich in factor VIII, fibrinogen (factor I), and vWF</td>
</tr>
</tbody>
</table>

<h3 id="adverseeffects">Adverse Effects </h3>

<p>Blood products have three main categories of adverse effects: metabolic, immune, and infectious.</p>

<ul>
<li>Metabolic: hyperkalemia (older PRBC), rarely hypocalcemia (citrate toxicity from FFP)</li>
<li>Immune: fever, acute/delayed hemolytic transfusion reaction, thrombocytopenia, anaphylaxis, urticaria, graft versus host disease (from donor WBC), immune suppression, TRALI (transfusion related acute lung reaction), TACO (transfusion associated circulatory overload)</li>
<li>Infectious: bacteremia (platelets highest risk), Hepatitis B (1 in 200 thousand), Hepatitis and HIV (1 in 2 million).</li>
</ul>

<h5 id="symptomstobeawareofposttransfusion">Symptoms to Be Aware of Post Transfusion </h5>

<ul>
<li>fever (increase in temp &gt;1&deg;C), pruritus, chills, hypotension, tachycardia, respiratory distress, rales, hives, flank pain, oozing from IV sites</li>
<li>acute transfusion reactions can present during or within 24 hours of transfusion - severe reactions within 15 minutes</li>
<li>TRALI may present 1&#8211;2 hours post transfusion but may be delayed (up to 72 hrs) - fever, hypotension, respiratory distress</li>
<li>GVHD may present 4&#8211;30 days post transfusion - fever, rash, nausea/vomiting, abdominal pain, profuse diarrhea, cough</li>
</ul>

<h2 id="coagulation">Coagulation </h2>

<p>Three coagulation pathways exist: intrinsic, extrinsic, common. Both intrinsic and extrinsic function is required for in vivo hemostasis. These pathways converge into a common pathway and require the presence of Ca<sup>2</sup>+.</p>

<table>
<colgroup>
<col />
<col />
<col />
<col />
</colgroup>

<thead>
<tr>
	<th>Pathway	</th>
	<th> Factors	</th>
	<th> Testing	</th>
	<th> Description	</th>
</tr>
</thead>

<tbody>
<tr>
	<td> <strong>Intrinsic</strong>	</td>
	<td> 12, 11, 9, 8	</td>
	<td> PTT/aPTT	</td>
	<td> <li>initiated by contact with abnormal/foreign surfaces <li>slower (2&#8211;6 min) than extrinsic	</td>
</tr>
<tr>
	<td> <strong>Extrinsic</strong>	</td>
	<td> 7	</td>
	<td> PT, INR	</td>
	<td> <li>initiated by tissue damage (exposure of tissue factor) <li>faster (15&#8211;20 sec) than intrinsic	</td>
</tr>
<tr>
	<td> <strong>Common</strong>	</td>
	<td> 10, 5, 2 (thrombin), 1 (fibrin)	</td>
	<td> measured as a part of PTT/PT	</td>
	<td> <li> formation of insoluble fibrin which is then cross-linked by factor 13 (fibrin + platelets = clot)</td>
</tr>
<tr>
</tr>
</tbody>
</table>

<h3 id="controlofbloodclotting">Control of Blood Clotting </h3>

<p>There are three groups of agents used to modify thrombus formation:</p>

<ol>
<li>anticoagulants - parenteral (heparin, LMWH), oral (warfarin, newer agents): used to prevent progression of clot formation
<li>fibrinolytic agents: used to eliminate existing clots
<li>anti-platelet agents: used to prevent initial clot formation
</ol>

<h4 id="heparin">Heparin </h4>

<ul>
<li>binds to antithrombin and increases the rate it inhibits coagulation factors Xa and IIa</li>
<li>therapeutic aPTT achieved in 24 hours</li>
<li>route of delivery: IV/SC</li>
<li>reversal agent: protamine sulfate (1 mg protamine : 100 units heparin)</li>
<li>~ 0.5% risk of HIT (heparin induced thrombocytopenia): platelets decrease to &lt; 50% of pretreatment value within 5&#8211;10 days after starting heparin</li>
</ul>

<h4 id="warfarin">Warfarin </h4>

<ul>
<li>vitamin K antagonist</li>
<li>requires monitoring of therapeutic index and has many drug-drug interactions</li>
<li>&downarrow; amount and function of vit K dependent coagulation factors II, VII, IX, X</li>
<li>&downarrow; vit K dependent anticoagulant proteins C and S</li>
<li>effects start at 24&#8211;36 hrs, therapeutic dose (INR 2.0&#8211;3.0) achieved in 5 days</li>
<li>route of delivery: oral</li>
<li>reversal agent: oral phytonadione (vitamin K<sub>1</sub>) - reestablishment of normal clotting factor activity in 24&#8211;48 hrs. Faster reversal with FFP and IV infusion of vitamin K.</li>
<li>surgery: stop 5 days prior</li>
</ul>

<h4 id="neworalanticoagulants">New Oral Anticoagulants </h4>

<p>Unlike warfarin, the new (direct) oral anticoagulants do not require monitoring of therapeutic levels and onset is quicker (between 1&#8211;3 hrs).</p>

<table>
<colgroup>
<col style="text-align:left;"/>
<col style="text-align:left;"/>
<col style="text-align:left;"/>
<col style="text-align:left;"/>
</colgroup>

<thead>
<tr>
	<th style="text-align:left;">Drug	</th>
	<th style="text-align:left;"> Target	</th>
	<th style="text-align:left;"> Reversible	</th>
	<th style="text-align:left;"> Surgery<br/>(# of hrs to stop prior to) </th>
</tr>
</thead>

<tbody>
<tr>
	<td style="text-align:left;">Xarelto (rivaroxiban)	</td>
	<td style="text-align:left;"> Xa	</td>
	<td style="text-align:left;"> No	</td>
	<td style="text-align:left;"> 24 </td>
</tr>
<tr>
	<td style="text-align:left;">Savaysa (edoxaban)</td>
	<td style="text-align:left;"> Xa </td>
	<td style="text-align:left;"> No </td>
	<td style="text-align:left;">24</td>
</tr>
<tr>
	<td style="text-align:left;">Eliquis (apixaban) </td>
	<td style="text-align:left;">Xa </td>
	<td style="text-align:left;">No</td>
	<td style="text-align:left;">48</td>
</tr>
<tr>
	<td style="text-align:left;">Pradaxa (dabigatran)</td>
	<td style="text-align:left;"> IIa (thrombin)</td>
	<td style="text-align:left;"> Yes (idarucizumab)</td>
	<td style="text-align:left;"> 48 </td>
</tr>
</tbody>
</table>

<p>See Thrombosis Canada for up to date guidelines and tools: <a href="http://thrombosiscanada.ca/tools/">http://thrombosiscanada.ca/tools/</a></p>

<h4 id="fibrinolytics">Fibrinolytics </h4>

<ul>
<li>three classes of fibrinolytic drugs: tissue plasminogen activator (tPA), streptokinase (SK), and urokinase (UK)</li>
<li>used for acute treatment of thrombosis e.g. tPA within the first 2 hours of MI</li>
</ul>

<h4 id="anti-platelet">Anti-platelet </h4>

<ul>
<li>reduction of platelet recruitment and activation

<ul>
<li>aspirin: irreversible COX-1 inhibitor</li>
<li>Plavix (clopidogrel): irreversible P2Y<sub>12</sub> inhibitor</li>
</ul></li>
<li>prevention of platelet aggregation: GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban)</li>
</ul>

<h1 id="sutures">Sutures </h1>

<p>Suture selection is based on tissue type. Considerations include how long tensile strength must be retained and how much tissue reactivity the material will cause.
Generally synthetic materials are less reactive and cause less tissue irritation.</p>

<p>Sutures are classified by how many filaments they have and by what material they are made of. Monofilament is less likely to harbour microbes than multifilament, but can be hard to tie securely. The material type determines how a suture breaks down. Absorbable sutures are broken down by proteolysis (natural suture materials), or hydrolysis (synthetic materials).</p>

<p>Suture size is based on thread diameter. The large the number, the thinner the thread. E.g. 8&#8211;0 - microvascular surgery, 2&#8211;0 deep tissues like bowel.</p>

<p>Needles attached to suturing thread are either tapered, conventional cutting, or reverse cutting. Cutting needles should only be used with skin, all other tissue should use a tapered needle so that tissue is not torn through.</p>

<p>Some common synthetic suture materials:
(<em>fa = fully absorbed</em>)</p>

<table>
<colgroup>
<col />
<col style="text-align:center;"/>
<col />
<col />
<col />
</colgroup>

<thead>
<tr>
	<th> Material </th>
	<th style="text-align:center;"> Absorbable?	</th>
	<th> Retention of Tensile Strength	</th>
	<th> Tissue Rx	</th>
	<th> Use	</th>
</tr>
</thead>

<tbody>
<tr>
	<td> Demalon (nylon)	</td>
	<td style="text-align:center;"> N	</td>
	<td> - 	</td>
	<td> low 	</td>
	<td> cutaneous	</td>
</tr>
<tr>
	<td> Prolene (polypropylene)	</td>
	<td style="text-align:center;"> N	</td>
	<td> -	</td>
	<td> low	</td>
	<td> cutaneous</td>
</tr>
<tr>
	<td> Mersilene (polyester)	</td>
	<td style="text-align:center;"> N	</td>
	<td> -	</td>
	<td> low 	</td>
	<td> soft tissue (long term approximation)	</td>
</tr>
<tr>
	<td> Monocryl (poliglecaprone)	</td>
	<td style="text-align:center;"> Y	</td>
	<td> 50% at 1 wk, 20% at 2 wks, fa in 100d	</td>
	<td> minimal	</td>
	<td> cutaneous</td>
</tr>
<tr>
	<td> Vicryl (lactide and glycoside)	</td>
	<td style="text-align:center;">Y </td>
	<td> 60% at 2 wks, 8% at 4 wks, fa in 60&#8211;90d	</td>
	<td> mild-moderate (less than catgut)	</td>
	<td> cutaneous (not the purple coated), soft tissue </td>
</tr>
<tr>
	<td> PDS (poly p-dioxanone) 	</td>
	<td style="text-align:center;"> Y</td>
	<td>70% at 2 wks, 50% at 4 wks, 25% at 6 wks, fa in 180d	</td>
	<td> minimal</td>
	<td> soft tissue requiring extended approximation, fascia </td>
</tr>
</tbody>
</table>

<p>Some common natural materials:</p>

<table>
<colgroup>
<col />
<col style="text-align:center;"/>
<col />
<col />
<col />
</colgroup>

<thead>
<tr>
	<th> Material </th>
	<th style="text-align:center;"> Absorbable?	</th>
	<th> Retention of Tensile Strength	</th>
	<th> Tissue Rx	</th>
	<th> Use	</th>
</tr>
</thead>

<tbody>
<tr>
	<td> silk	</td>
	<td style="text-align:center;"> N	</td>
	<td> 2 years	</td>
	<td> moderate	</td>
	<td> soft tissue approximation/ligation	</td>
</tr>
<tr>
	<td> catgut	</td>
	<td style="text-align:center;"> Y	</td>
	<td> 7&#8211;10 days, fa 70 days	</td>
	<td> moderate	</td>
	<td> soft tissue	</td>
</tr>
<tr>
	<td> chromic gut	</td>
	<td style="text-align:center;"> Y	</td>
	<td> 14 days, fa 90 days	</td>
	<td> moderate (&lt; plain gut)	</td>
	<td> soft tissue approximation/ligation</td>
</tr>
</tbody>
</table>

<p>For more information please see <a href="http://www.dermnetnz.org/topics/suture-materials/">http://www.dermnetnz.org/topics/suture-materials/</a></p>

<h2 id="generalrules">General Rules </h2>

<ul>
<li>3&#8211;0 or 4&#8211;0 sutures are used for skin on the torso and extremities</li>
<li>5&#8211;0 or 6&#8211;0 sutures are used for skin on the face and neck</li>
<li>2&#8211;0 to 4&#8211;0 sutures are used for closure of deeper tissues</li>
<li>non-absorbable sutures should be removed in:

<ul>
<li>7&#8211;10 days - torso and extremities</li>
<li>4 days - face and neck</li>
</ul></li>
<li>cosmetic procedures use non-absorbable sutures</li>
</ul>

</main>


</body>
</html>

